Status:
COMPLETED
Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer
Lead Sponsor:
IrsiCaixa
Conditions:
HIV Infection
Cancer
Eligibility:
All Genders
Brief Summary
It has been reported that peripheral and lymph node resident Cluster of Differentiation 4 (CD4)+ T cells expressing Programmed cell death protein 1 (PD-1) contribute to Human Immunodeficiency Virus (H...
Detailed Description
Long-lived latently infected resting CD4+ T cells are the main reason why current antiretroviral therapy (ART) is unable to cure HIV infection. Recent work has suggested that the expression of immune ...
Eligibility Criteria
Inclusion
- HIV-infected subjects with advanced melanoma or other oncological conditions in which the use of immunological checkpoint inhibitors is clinically indicated
Exclusion
- None
Key Trial Info
Start Date :
October 26 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 11 2019
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03767465
Start Date
October 26 2018
End Date
October 11 2019
Last Update
January 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916